Nurix Therapeutics, Inc. (NRIX) has disclosed a new risk, in the Capital Markets category.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nurix Therapeutics, Inc. faces meaningful foreign exchange risk as it incurs a portion of its expenses, and may in the future earn revenues, in multiple currencies. Its reported results of operations and cash flows could fluctuate materially when translated into U.S. dollars if exchange rates move adversely. This risk could increase if a larger share of its cost base or revenue stream becomes denominated in foreign currencies or if U.S. government actions drive further volatility in the dollar’s relative value. Since the company does not currently hedge its currency exposure, it remains fully vulnerable to potentially adverse foreign exchange movements, which could negatively impact its business, financial condition, operating results, and prospects.
Overall, Wall Street has a Strong Buy consensus rating on NRIX stock based on 14 Buys.
To learn more about Nurix Therapeutics, Inc.’s risk factors, click here.